Premium
Pharmacological evaluation of a new series of benzofuran‐2‐ carboxamides as antihyperlipidemic agents in rats
Author(s) -
AlQirim Tariq Musbah,
Shattat Ghassan,
Sweidan Kamal,
Sheikha Ghassan Abu
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb168
Subject(s) - benzofuran , hyperlipidemia , triglyceride , chemistry , in vivo , pharmacology , cholesterol , medicine , endocrinology , stereochemistry , biochemistry , diabetes mellitus , biology , microbiology and biotechnology
The aim of this study is to investigate the pharmacological activity of a new series of benzofuran‐2‐carboxamides (3a‐3d and 4a′‐4c′). Compounds (3a, 3b, and 4a′—4c′) were tested in vivo using Triton‐WR‐1339‐induced hyperlipidemic rats as an experimental model. The tested animals were divided into eight groups: control, hyperlipidemic, compounds 3a, 3b, 4a′, 4b′, 4c′, and beza□brate. At a dose of 15 mg/kg, the elevated plasma triglyceride (TG) levels were signi□cantly reduced in compounds 3b (p<0.0001) and 4c′ (p <0.05) after 12 and 24 h compared to the normal control group. Furthermore, high‐density lipoprotein‐cholesterol levels were remarkably increased in compounds 3b (p<0.001) and 4c′ (p <0.05). Meanwhile, compound 4b′ slightly reduced the TG levels after 12 and 24 h. The present study demonstrated new properties of the novel series benzofuran‐2‐carboxamides 3b and 4c′ as potent lipid‐lowering agents. It is, therefore, reasonable to assume that compounds 3b and 4c′ may have a promising potential in the treatment of hyperlipidemia and coronary heart diseases. This research is financially supported by Al‐Zaytoonah University of Jordan